Regeneron announces acquisition of 2seventy bio’s R&D unit, formation of Regeneron Cell Medicines

2seventy bio has entered into an asset purchase agreement (APA) with Regeneron Pharmaceuticals to sell the its oncology and autoimmune research and development programs, clinical manufacturing capabilities, and related platform technologies as part of a company-wide strategic re-alignment. Concurrent with this news, Regeneron announced it will take the assets acquired from 2seventy bio and form Regeneron Cell Medicines, which will be led by 2seventy bio’s Chief Scientific Officer, Philip Gregory, D.Phil., who will be appointed Senior Vice President.

In 2018 Regeneron and bluebird bio - which subsequently spun out 2seventy bio in 2021- entered into an agreement to leverage their complementary technologies for the discovery of novel cell therapies against cancer. Under this agreement, Regeneron had the right to opt-in to a co-development/co-commercialization arrangement for collaboration targets.